Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX ‐1/2 Phase 3 Studies
Summary We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU. Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.
Authors
- Michihiro Hide (ORCID: https://orcid.org/0000-0002-1569-6034)
- Nadine Chapman‐Rothe
- Atsushi Fukunaga (ORCID: https://orcid.org/0000-0003-2026-8154)
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Giselle S Mosnaim (ORCID: https://orcid.org/0000-0002-9874-3472)
- Ansgar J. Weyergraf (ORCID: https://orcid.org/0000-0001-5221-2492)
- Ana Maria Giménez‐Arnau (ORCID: https://orcid.org/0000-0001-5434-7753)
- E.D. Martzloff
- Hui Tang (ORCID: https://orcid.org/0000-0002-8525-9147)
- Gordon Lloyd Sussman
- Christine-Elke Ortmann
- P.G.P Machado
- Tao Ding
- Petra Staubach
- Bin Yang
- John Reed (ORCID: https://orcid.org/0000-0002-9771-8371)
Institutions
- Hiroshima University (JP)
- Novartis (Switzerland) (CH)
- Shanghai Medical College of Fudan University (CN)
- Universitat Pompeu Fabra (ES)
- University of Toronto (CA)
- Osaka Medical and Pharmaceutical University (JP)
- Fudan University (CN)
- Churchill Hospital (GB)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Leiber (Germany) (DE)
- Huashan Hospital (CN)
- Hiroshima City Hiroshima Citizens Hospital (JP)
- Southern Medical University (CN)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2026-10-18
- DOI
- https://doi.org/10.1111/cea.70450
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00